{
  "id": "resp_04dfd845f8c3c9b900693c90014c4881948bc211b5cbff4484",
  "object": "response",
  "created_at": 1765576705,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_04dfd845f8c3c9b900693c9001baf08194a897424a7998d1c2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c900398888194b0eba7722be56642",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT CDK12/13 inhibitor"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c900534488194a3c6dc23e191db7c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c9006afb081948a638eb6ab09b921",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT CT7439"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c9008797c81948aeec1e497a9f672",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c90099a408194849b9a33e4917230",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrialsregister.eu CDK12 CDK13 inhibitor"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c900bd2808194a06371c1a54f0b99",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c900d615481948411306ecc602ed7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT CDK12 inhibitor phase 1"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c900f80a8819492643c9d630b2579",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c901279b08194b12bf6f8ec1f0532",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"EudraCT\" \"CDK12\""
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c9014d6dc81948bbde9370398c749",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c90162ed08194b771cb71a13fd23e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu \"CDK12\""
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c901a8bf88194b71d44d7a4c56053",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c9024b79881949bdcc8b65f5e8500",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c9028100481949e7b4207270f7059",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c9029b0488194863864493bd2c38e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "SR-4835",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c902edab481949f6e8d06fdf312d2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c9030812881949294620526f63f0e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu \"CDK12/13\""
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c9033f4d4819481642ae42c3c10b5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c90363bb88194ac096af44bc6bea0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "EGFR",
        "url": "https://www.mdpi.com/2072-6694/15/8/2263"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c9038831c81949ac503bd1e082e88",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c903b79cc819482f8dfb1b11dac3c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "generate compound",
        "url": "https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00190g"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c903f34e48194a2798c41fd0db6ae",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c90418bb88194a44a70452fb771ac",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "##  Abstract",
        "url": "https://pubmed.ncbi.nlm.nih.gov/33945934/"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c904475708194b3f394bb49392a0a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c9048b3948194ac249f1b233109b7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CT7439 patent WO"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c904cf4dc819489c0a50dc817aae1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04dfd845f8c3c9b900693c904ed7948194b13fb5f2ecf15e15",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://patents.google.com/patent/WO2019217421A1/en"
      }
    },
    {
      "id": "rs_04dfd845f8c3c9b900693c905102cc8194baffcab98d9f65bc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_04dfd845f8c3c9b900693c90661ad48194ae70d90008d6906c",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 815,
              "start_index": 615,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1229,
              "start_index": 1159,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 1800,
              "start_index": 1746,
              "title": "Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance | MDPI",
              "url": "https://www.mdpi.com/2072-6694/15/8/2263"
            },
            {
              "type": "url_citation",
              "end_index": 2387,
              "start_index": 2317,
              "title": "Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33945934/"
            },
            {
              "type": "url_citation",
              "end_index": 2893,
              "start_index": 2823,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 3477,
              "start_index": 3397,
              "title": "Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K   - RSC Chemical Biology (RSC Publishing) DOI:10.1039/D4CB00190G",
              "url": "https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00190g"
            },
            {
              "type": "url_citation",
              "end_index": 3834,
              "start_index": 3746,
              "title": "EUB0001632a_CDK13 | EUbOPEN",
              "url": "https://www.eubopen.org/chemogenomics/chemogenomic-set/eub0001632acdk13"
            },
            {
              "type": "url_citation",
              "end_index": 4351,
              "start_index": 4276,
              "title": "WO2019217421A1 - Small molecule inhibitors of cdk12/cdk13 \n        - Google Patents",
              "url": "https://patents.google.com/patent/WO2019217421A1/en"
            }
          ],
          "logprobs": [],
          "text": "- **Title:** Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)  \n  **URL:** `https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html`  \n  **Direct quote snippets:**  \n  - “Phase 1 clinical trial evaluating **CT7439**, a novel cyclin dependent kinase 12/13 (**CDK12/13**) inhibitor / **Cyclin-K glue-degrader**.”  \n  - “advanced solid tumors, including **ovarian, breast and Ewing's Sarcoma**.”  \n  - “under study ID: **NCT06600789**.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n\n- **Title:** Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/31668947/`  \n  **Direct quote snippets:**  \n  - “development of **SR-4835**, a highly selective dual inhibitor of **CDK12** and **CDK13**”  \n  - “disables **triple-negative breast cancer (TNBC)** cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n\n- **Title:** Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance (MDPI)  \n  **URL:** `https://www.mdpi.com/2072-6694/15/8/2263`  \n  **Direct quote snippets:**  \n  - “two novel **CDK12/13 inhibitors, AU-15506 and AU-16770**, in **osimertinib-resistant EGFR mutant lung adenocarcinoma**”  \n  - “inhibition of **CDK12/13** in combination with **osimertinib** has the potential to overcome **osimertinib resistance**” ([mdpi.com](https://www.mdpi.com/2072-6694/15/8/2263))\n\n- **Title:** Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/33945934/`  \n  **Direct quote snippets:**  \n  - “We previously described **THZ531**, a **covalent inhibitor** with selectivity for **CDK12/13**.”  \n  - “**BSJ-01-175** exhibits efficacy against an **Ewing sarcoma** tumor growth in a patient-derived xenograft (**PDX**) mouse model” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33945934/))\n\n- **Title:** Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/34864331/`  \n  **Direct quote snippets:**  \n  - “**PP-C8** demonstrates profound synergistic antiproliferative effects with **PARP inhibitor** in **triple-negative breast cancer (TNBC)**.”  \n  - “selective **CDK12 PROTAC degrader**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n\n- **Title:** Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K (RSC Chemical Biology)  \n  **URL:** `https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00190g`  \n  **Direct quote snippets:**  \n  - “generate compound **MR-1226** (Fig. 5A). **MR-1226** effectively degraded cyclin K with a **DC _{50} of 50 nM**”  \n  - “The **CDK12 inhibitor SR-4835** facilitates potent **molecular glue** activity enabling the degradation of cyclin K” ([pubs.rsc.org](https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00190g))\n\n- **Title:** EUB0001632a_CDK13 | EUbOPEN  \n  **URL:** `https://www.eubopen.org/chemogenomics/chemogenomic-set/eub0001632acdk13`  \n  **Direct quote snippets:**  \n  - “Compound name **SR-4835**”  \n  - “Target name **CDK13**”  \n  - “Compound EUbOPEN ID **EUB0001632a**” ([eubopen.org](https://www.eubopen.org/chemogenomics/chemogenomic-set/eub0001632acdk13))\n\n- **Title:** WO2019217421A1 — Small molecule inhibitors of cdk12/cdk13 (Google Patents)  \n  **URL:** `https://patents.google.com/patent/WO2019217421A1/en`  \n  **Direct quote snippets:**  \n  - “Publication number **WO2019217421A1**”  \n  - “the only selective inhibitor of **CDK12/13** reported so far - **THZ531**”  \n  - “use in targeted treatment of variety of cancers including **breast cancer**, **brain cancer** and **ovarian cancer**.” ([patents.google.com](https://patents.google.com/patent/WO2019217421A1/en))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 63531,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 6159,
    "output_tokens_details": {
      "reasoning_tokens": 4925
    },
    "total_tokens": 69690
  },
  "user": null,
  "metadata": {}
}